TECHNODRUG

Techno Drugs Ltd. · Pharmaceuticals and Chemicals · Cat A

37/100

Weak

৳42.5

DSE Hexagon

Stands out for a solid balance sheet, held back by looks fully priced.

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (2)

⚠ Earnings trending down
⚠ Financial health deteriorating

Rewards (0)

No notable positives flagged.

Score breakdown

Price history & performance

52-week high৳46.0

52-week low৳26.9

From 52w high-7.6%

Beta1.1

7D -1.4%

1M -2.5%

3M +20.4%

6M +48.1%

1Y +50.7%

YTD +44.1%

Shareholder returns vs DSEX

TECHNODRUG-2.1%

DSEX+2.4%

TECHNODRUG underperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility46.6%

Daily VaR (95%)-3.5%

Max drawdown (5y)-60.3%

Correlation to market0.53

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)49.9

MACDbearish

Bollingerinside bands (-0.5σ)

Price cycle (Wyckoff)

Health trenddeteriorating

Flow pressuredistribution

Valuation

Fair value31.7 (22.2-41.2)

Upside-25.00%

Dividend yield+2.30%

Fundamental verdictWATCH

ConfidenceLOW (re-rate ceiling, not target)

Ownership

Institutional holding6.3%

Foreign holding0.0%

Free float30.99%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳2,000mn

Paid-up capital৳1,319.98mn

Face value৳10

Market lot1

Outstanding shares131,998,188

Last AGM24-12-2025

Fiscal year end30-Jun

Reserve & surplus (ex-OCI)৳2,716mn

Other comprehensive income৳0mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E

Jul 14, 2026 27.39 28.17

Jul 13, 2026 27.01 27.78

Jul 12, 2026 27.08 27.84

Jul 9, 2026 27.71 28.5

Jul 8, 2026 27.58 28.37

Jul 7, 2026 27.65 28.43

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

202510%

202412%

Earnings & NAV

YearEPSNAVDividend

2025 1.76 30.58 10%

2024 2.94 33.5 12%

Quarterly EPS — FY2026

Q10.47

Q20.4

Half-year0.87

Q30.31

Nine-month1.18

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳46.3

Support

৳40.4

৳38.1

৳35.1

৳33

Historical bounce zones

Feb 5, 2026: ৳28.4→৳34 +20%

Mar 8, 2026: ৳27.4→৳35.9 +31%

Apr 5, 2026: ৳33→৳38.4 +16%

Apr 27, 2026: ৳35→৳41.9 +20%

May 11, 2026: ৳38.1→৳47.1 +24%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

ScripScorePriceUpsideYield

IBNSINAThe IBN SINA Pharmaceutical Industry PLC 87 ৳326.5 +12.00% +2.00%MARICOMarico Bangladesh Limited 87 ৳2,732.4 +24.00% +2.20%SQURPHARMASquare Pharmaceuticals PLC. 85 ৳221.4 +120.00% +5.40%ACMELABThe ACME Laboratories Limited 79 ৳86.9 +138.00% +4.10%BXPHARMABeximco Pharmaceuticals PLC. 78 ৳153.2 +54.00% +2.60%RENATARenata PLC 64 ৳464.3 -25.00% +1.20%

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -5% / -1% / 3.8%

30-day 41% vs 42% market avg Typical move: -8.9% / -1.8% / 6.6%

Signals: Three Outside Down

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readWAIT (until clears both axes)

Reference stopn/a

Reference target—

Timing notewatch; no fresh money

Elevated (score 138) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: DORMANT (23% >200-MA, flow ACC). [fundamentals WATCH, payout 57.0%, yield 2.3%]